Does the media refer more to ARQT or PURR?

In the previous week, Arcutis Biotherapeutics had 19 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 21 mentions for Arcutis Biotherapeutics and 2 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.81 beat Arcutis Biotherapeutics' score of 0.78 indicating that Hyperliquid Strategies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 9 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Hyperliquid Strategies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PURR or ALMS?

In the previous week, Alumis had 19 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 21 mentions for Alumis and 2 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.81 beat Alumis' score of 0.39 indicating that Hyperliquid Strategies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperliquid Strategies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, TLX or PURR?

Telix Pharmaceuticals has higher revenue and earnings than Hyperliquid Strategies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.50 -$7.12M N/A N/A Hyperliquid Strategies $1M 963.48 -$16.01M -$7.37 N/A

Is TLX or PURR more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Hyperliquid Strategies' return on equity. Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A Hyperliquid Strategies N/A -56.04% -52.22%

Does the media prefer TLX or PURR?

In the previous week, Telix Pharmaceuticals had 5 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 7 mentions for Telix Pharmaceuticals and 2 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.81 beat Telix Pharmaceuticals' score of 0.42 indicating that Hyperliquid Strategies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Hyperliquid Strategies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RCUS or PURR?

In the previous week, Arcus Biosciences had 11 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 13 mentions for Arcus Biosciences and 2 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.81 beat Arcus Biosciences' score of 0.52 indicating that Hyperliquid Strategies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Hyperliquid Strategies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PURR or GPCR more profitable?

Structure Therapeutics' return on equity of -24.91% beat Hyperliquid Strategies' return on equity. Company Net Margins Return on Equity Return on Assets Hyperliquid Strategies N/A -56.04% -52.22% Structure Therapeutics N/A -24.91% -23.67%

Does the media prefer PURR or GPCR?

In the previous week, Structure Therapeutics had 3 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 5 mentions for Structure Therapeutics and 2 mentions for Hyperliquid Strategies. Structure Therapeutics' average media sentiment score of 0.96 beat Hyperliquid Strategies' score of 0.81 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperliquid Strategies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Hyperliquid Strategies (PURR) Competitors

$6.67 -0.15 (-2.20%)

Closing price 04:00 PM Eastern

Extended Trading

$6.70 +0.03 (+0.37%)

As of 06:03 PM Eastern

Compare

PURR vs. ARQT, ALMS, TLX, RCUS, and GPCR

Should you buy Hyperliquid Strategies stock or one of its competitors? MarketBeat compares Hyperliquid Strategies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hyperliquid Strategies include Arcutis Biotherapeutics (ARQT), Alumis (ALMS), Telix Pharmaceuticals (TLX), Arcus Biosciences (RCUS), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

How does Hyperliquid Strategies compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Hyperliquid Strategies (NASDAQ:PURR) are related companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Hyperliquid Strategies has lower revenue, but higher earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$415.62M	7.95	-$16.14M	-$0.03	N/A
Hyperliquid Strategies	$1M	963.48	-$16.01M	-$7.37	N/A

Arcutis Biotherapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market.

Arcutis Biotherapeutics presently has a consensus price target of $35.57, indicating a potential upside of 34.59%. Hyperliquid Strategies has a consensus price target of $12.72, indicating a potential upside of 90.65%. Given Hyperliquid Strategies' higher possible upside, analysts clearly believe Hyperliquid Strategies is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Arcutis Biotherapeutics had 19 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 21 mentions for Arcutis Biotherapeutics and 2 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.81 beat Arcutis Biotherapeutics' score of 0.78 indicating that Hyperliquid Strategies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	9 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Hyperliquid Strategies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.5% of Hyperliquid Strategies shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Hyperliquid Strategies has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

Summary

Arcutis Biotherapeutics and Hyperliquid Strategies tied by winning 8 of the 16 factors compared between the two stocks.

How does Hyperliquid Strategies compare to Alumis?

Hyperliquid Strategies (NASDAQ:PURR) and Alumis (NASDAQ:ALMS) are related companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

9.5% of Hyperliquid Strategies shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by company insiders. Comparatively, 33.7% of Alumis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Hyperliquid Strategies currently has a consensus target price of $12.72, indicating a potential upside of 90.65%. Alumis has a consensus target price of $40.30, indicating a potential upside of 44.96%. Given Hyperliquid Strategies' higher possible upside, equities research analysts clearly believe Hyperliquid Strategies is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Hyperliquid Strategies has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Hyperliquid Strategies' return on equity of -56.04% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Alumis	-2,825.70%	-88.79%	-70.72%

Hyperliquid Strategies has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	963.48	-$16.01M	-$7.37	N/A
Alumis	$8.40M	421.84	-$243.32M	-$1.98	N/A

In the previous week, Alumis had 19 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 21 mentions for Alumis and 2 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.81 beat Alumis' score of 0.39 indicating that Hyperliquid Strategies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperliquid Strategies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hyperliquid Strategies has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market. Comparatively, Alumis has a beta of -0.69, suggesting that its share price is 169% less volatile than the broader market.

Summary

Hyperliquid Strategies beats Alumis on 10 of the 17 factors compared between the two stocks.

How does Hyperliquid Strategies compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Hyperliquid Strategies (NASDAQ:PURR) are related companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Telix Pharmaceuticals currently has a consensus price target of $20.40, indicating a potential upside of 91.73%. Hyperliquid Strategies has a consensus price target of $12.72, indicating a potential upside of 90.65%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Telix Pharmaceuticals is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Telix Pharmaceuticals has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market.

Telix Pharmaceuticals has higher revenue and earnings than Hyperliquid Strategies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.50	-$7.12M	N/A	N/A
Hyperliquid Strategies	$1M	963.48	-$16.01M	-$7.37	N/A

Telix Pharmaceuticals' return on equity of 0.00% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Hyperliquid Strategies	N/A	-56.04%	-52.22%

9.5% of Hyperliquid Strategies shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Telix Pharmaceuticals had 5 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 7 mentions for Telix Pharmaceuticals and 2 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.81 beat Telix Pharmaceuticals' score of 0.42 indicating that Hyperliquid Strategies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Hyperliquid Strategies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Telix Pharmaceuticals beats Hyperliquid Strategies on 9 of the 14 factors compared between the two stocks.

How does Hyperliquid Strategies compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Hyperliquid Strategies (NASDAQ:PURR) are related companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Arcus Biosciences had 11 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 13 mentions for Arcus Biosciences and 2 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.81 beat Arcus Biosciences' score of 0.52 indicating that Hyperliquid Strategies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Hyperliquid Strategies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcus Biosciences has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market.

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 9.5% of Hyperliquid Strategies shares are held by institutional investors. 7.6% of Arcus Biosciences shares are held by insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Hyperliquid Strategies has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$236M	15.04	-$353M	-$3.18	N/A
Hyperliquid Strategies	$1M	963.48	-$16.01M	-$7.37	N/A

Arcus Biosciences presently has a consensus target price of $36.90, indicating a potential upside of 30.71%. Hyperliquid Strategies has a consensus target price of $12.72, indicating a potential upside of 90.65%. Given Hyperliquid Strategies' higher possible upside, analysts clearly believe Hyperliquid Strategies is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Hyperliquid Strategies has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Hyperliquid Strategies' return on equity of -56.04% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

Summary

Hyperliquid Strategies beats Arcus Biosciences on 9 of the 16 factors compared between the two stocks.

How does Hyperliquid Strategies compare to Structure Therapeutics?

Hyperliquid Strategies (NASDAQ:PURR) and Structure Therapeutics (NASDAQ:GPCR) are related companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Structure Therapeutics had 3 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 5 mentions for Structure Therapeutics and 2 mentions for Hyperliquid Strategies. Structure Therapeutics' average media sentiment score of 0.96 beat Hyperliquid Strategies' score of 0.81 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperliquid Strategies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hyperliquid Strategies has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	963.48	-$16.01M	-$7.37	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Hyperliquid Strategies currently has a consensus price target of $12.72, indicating a potential upside of 90.65%. Structure Therapeutics has a consensus price target of $110.55, indicating a potential upside of 110.08%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

9.5% of Hyperliquid Strategies shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Structure Therapeutics' return on equity of -24.91% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Structure Therapeutics	N/A	-24.91%	-23.67%

Hyperliquid Strategies has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.43, indicating that its stock price is 243% less volatile than the broader market.

Summary

Structure Therapeutics beats Hyperliquid Strategies on 10 of the 15 factors compared between the two stocks.

Get Hyperliquid Strategies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PURR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PURR vs. The Competition

Export

Metric	Hyperliquid Strategies	Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$963.48M	$2.94B	$10.77B	$12.84B
Dividend Yield	N/A	13.72%	120.64%	9.78%
P/E Ratio	-0.91	13.45	28.71	25.43
Price / Sales	963.48	4,795.07	435.48	80.37
Price / Cash	N/A	124.43	24.81	50.79
Price / Book	4.39	17.58	4.56	6.06
Net Income	-$16.01M	-$13.54M	$609.70M	$348.34M
7 Day Performance	5.87%	1.18%	2.87%	3.03%
1 Month Performance	-24.38%	-0.07%	-0.77%	-3.04%
1 Year Performance	N/A	10.98%	13.67%	20.65%

Hyperliquid Strategies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PURR Hyperliquid Strategies	2.0882 of 5 stars	$6.67 -2.2%	$12.72 +90.7%	N/A	$963.48M	$1M	N/A	N/A	Gap Down
ARQT Arcutis Biotherapeutics	3.9365 of 5 stars	$28.01 -1.4%	$34.00 +21.4%	+76.9%	$3.48B	$376.07M	N/A	150	Trending News Earnings Report Analyst Forecast Insider Trade Gap Up
ALMS Alumis	4.0945 of 5 stars	$27.11 +0.3%	$40.30 +48.7%	+545.7%	$3.48B	$24.05M	N/A	N/A	Trending News Upcoming Earnings Analyst Forecast
TLX Telix Pharmaceuticals	4.1396 of 5 stars	$10.20 +0.0%	$20.40 +100.1%	-15.0%	$3.46B	$803.79M	N/A	1,184
RCUS Arcus Biosciences	3.0922 of 5 stars	$27.14 +0.3%	$36.40 +34.1%	+192.3%	$3.45B	$247M	N/A	500	Trending News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PURR) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hyperliquid Strategies (PURR) Competitors

PURR vs. ARQT, ALMS, TLX, RCUS, and GPCR

How does Hyperliquid Strategies compare to Arcutis Biotherapeutics?

Summary

How does Hyperliquid Strategies compare to Alumis?

Summary

How does Hyperliquid Strategies compare to Telix Pharmaceuticals?

Summary

How does Hyperliquid Strategies compare to Arcus Biosciences?

Summary

How does Hyperliquid Strategies compare to Structure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PURR vs. The Competition

Hyperliquid Strategies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hyperliquid Strategies (PURR) Competitors

PURR vs. ARQT, ALMS, TLX, RCUS, and GPCR

How does Hyperliquid Strategies compare to Arcutis Biotherapeutics?

Which has preferable earnings & valuation, ARQT or PURR?

Which has more volatility & risk, ARQT or PURR?

Do analysts recommend ARQT or PURR?

Does the media refer more to ARQT or PURR?

Do institutionals and insiders believe in ARQT or PURR?

Is ARQT or PURR more profitable?

Summary

How does Hyperliquid Strategies compare to Alumis?

Do insiders and institutionals believe in PURR or ALMS?

Do analysts rate PURR or ALMS?

Is PURR or ALMS more profitable?

Which has preferable valuation and earnings, PURR or ALMS?

Does the media favor PURR or ALMS?

Which has more risk & volatility, PURR or ALMS?

Summary

How does Hyperliquid Strategies compare to Telix Pharmaceuticals?

Do analysts rate TLX or PURR?

Which has more volatility & risk, TLX or PURR?

Which has higher valuation & earnings, TLX or PURR?

Is TLX or PURR more profitable?

Do insiders & institutionals believe in TLX or PURR?

Does the media prefer TLX or PURR?

Summary

How does Hyperliquid Strategies compare to Arcus Biosciences?

Does the media refer more to RCUS or PURR?

Which has more volatility & risk, RCUS or PURR?

Do institutionals and insiders believe in RCUS or PURR?

Which has higher earnings & valuation, RCUS or PURR?

Do analysts prefer RCUS or PURR?

Is RCUS or PURR more profitable?

Summary

How does Hyperliquid Strategies compare to Structure Therapeutics?

Does the media prefer PURR or GPCR?

Which has stronger valuation and earnings, PURR or GPCR?

Do analysts rate PURR or GPCR?

Do institutionals & insiders believe in PURR or GPCR?

Is PURR or GPCR more profitable?

Which has more risk & volatility, PURR or GPCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PURR vs. The Competition

Hyperliquid Strategies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools